Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

81. Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety

Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety TITLE: Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety DATE: 02 July 2013 CONTEXT AND POLICY ISSUES Low molecular weight heparins (LMWH) have emerged as an important alternative to unfractionated heparin (...) . LMWH are at least as effective antithrombotic drugs as UFH, however, it is still unclear whether the safety profiles of LMWH and UFH differ. 12 The important adverse events of heparin includes heparin-induced thrombocytopenia (HIT), an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet activation, 13 and bleeding. In 2009, CADTH published a review on the cost-effectiveness of LMWH compared with UFH. 11 It was reported in that review that LMWH appeared

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

82. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. (Abstract)

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular

2013 Cochrane

83. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. (Abstract)

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Sickle cell disease is one of the most common and severe genetic disorders in the world. It can be broadly divided into two distinct clinical phenotypes characterized by either haemolysis or vaso-occlusion. Pain is the most prominent symptom of vaso-occlusion, and hypercoagulability is a well-established pathogenic phenomenon in people with sickle cell disease. Low-molecular-weight heparins (...) might control this hypercoagulable state through their anticoagulant effect.To assess the effects of low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches. We also searched abstract books of conference proceedings and several online trials registries for ongoing

2013 Cochrane

84. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial

Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2013 PedsCCM Evidence-Based Journal Club

85. Methods for administering subcutaneous heparin during pregnancy. (Abstract)

Methods for administering subcutaneous heparin during pregnancy. Pregnant women with a history of venous thromboembolism (VTE), antithrombin deficiency, or other risk factors for VTE, need heparin (unfractionated heparin (UFH) or low-molecular weight heparin (LMWH)) prophylaxis, mainly through administering subcutaneously. Several methods of administering heparin (UFH or LMWH) subcutaneously have been introduced to prevent adverse pregnant outcomes. The effectiveness and safety of different (...) methods administering subcutaneous heparin (UFH or LMWH) during pregnancy have not been systematically evaluated.To compare the effectiveness and safety of different methods of administering subcutaneous heparin (UFH or LMWH) to pregnant women.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2013) and reference lists of retrieved studies.All randomised controlled trials (individual and cluster) comparing the effectiveness and safety of different methods

2013 Cochrane

86. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Full Text available with Trip Pro

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic (...) unfractionated heparin, to prevent venous thromboembolism, after an acute ischaemic stroke. The authors concluded that the higher cost of enoxaparin was offset by fewer clinical events, compared with unfractionated heparin, particularly for patients with more severe stroke. The study focused on the economic data and was satisfactorily carried out. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-effectiveness analysis Study objective This study examined the clinical and economic

2013 NHS Economic Evaluation Database.

87. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Full Text available with Trip Pro

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk.This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo

2013 Cochrane

88. Thromboelastography-guided heparin use for the prevention of venous thromboembolism

Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Thromboelastography-guided heparin use for the prevention of venous thromboembolism Mitchell MD, Fishman N, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Fishman N (...) , Umscheid CA. Thromboelastography-guided heparin use for the prevention of venous thromboembolism. Philadelphia: Center for Evidence-based Practice (CEP). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Heparin; Humans; Venous Thromboembolism Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535

2013 Health Technology Assessment (HTA) Database.

89. Low Molecular Weight Heparin Volume for Single Site Injection: Evidence-Based Guidelines and Safety

Low Molecular Weight Heparin Volume for Single Site Injection: Evidence-Based Guidelines and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Low Molecular Weight Heparin

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

90. The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis

The treatment of venous thromboembolism with low-molecular-weight heparins: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

91. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines

Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

92. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence

Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dual antiplatelet therapy and enoxaparin or unfractionated heparin for patients with ST-elevation myocardial infarction: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions No relevant studies were identified that compared the clinical

2012 Health Technology Assessment (HTA) Database.

93. Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence

Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could (...) -commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

94. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis

Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

95. Heparin-induced skin lesions. (Abstract)

Heparin-induced skin lesions. Heparins are widely used for prophylaxis and treatment of thromboembolic diseases. Besides bleeding complications, heparin-induced skin lesions are the most frequent unwanted adverse effects of subcutaneous heparin treatment. Evidence suggests that these lesions are more common than previously thought. Lesions are most frequently due to either allergic reactions or to possibly life-threatening heparin-induced thrombocytopenia. Early recognition and adequate (...) treatment are highly important, because although both complications initially show a similar clinical picture, their treatment should be fundamentally different. Furthermore, risk factors associated with the patient, drug, and treatment regimen have been identified. We review the clinical range of heparin-induced skin lesions, emphasise evidence and controversies in epidemiology, diagnosis, and differential diagnosis, and discuss the management of patients with these skin lesions.Copyright © 2012

2012 Lancet

96. Early intravenous unfractionated heparin and mortality in septic shock

Early intravenous unfractionated heparin and mortality in septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

97. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Full Text available with Trip Pro

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis Wilbur K, Lynd LD, Sadatsafavi M Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of low-dose unfractionated heparin versus low-molecular weight heparin (LMWH) for the prevention of venous thromboembolism, in patients hospitalised for non-surgical

2012 NHS Economic Evaluation Database.

98. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction Full Text available with Trip Pro

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.Cost-utility analysis with life-long time horizon.Costs, quality

2012 EvidenceUpdates Controlled trial quality: uncertain

99. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis Silvain J, Beygui F, Barthelemy O, Pollack C, Cohen M, Zeymer U, Huber (...) K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G CRD summary The review concluded that enoxaparin seemed to be superior to unfractionated heparin in reducing mortality and bleeding outcomes during percutaneous coronary intervention, particularly for primary intervention in patients with ST elevation myocardial infarction. The authors' conclusions appear reasonable and are likely to be reliable. Authors' objectives To determine the efficacy and safety of enoxaparin compared

2012 DARE.

100. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.